{"id":"NCT04129398","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042)","officialTitle":"A Phase 3, Open-Label, Single-Arm Clinical Study to Evaluate the Safety, Efficacy and Pharmacokinetics of MK-8228 (Letermovir) for the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-12-27","primaryCompletion":"2022-10-06","completion":"2022-10-06","firstPosted":"2019-10-16","resultsPosted":"2024-04-01","lastUpdate":"2024-08-21"},"enrollment":22,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Cytomegalovirus Infection","Cytomegalovirus Disease"],"interventions":[{"type":"DRUG","name":"Letermovir tablet","otherNames":["MK-8228","PREVYMIS®"]},{"type":"DRUG","name":"Letermovir IV","otherNames":["MK-8228","PREVYMIS®"]}],"arms":[{"label":"Letermovir","type":"EXPERIMENTAL"}],"summary":"This study aims to evaluate the safety, efficacy and pharmacokinetics (PK) of Letermovir (LET) administered as prevention of cytomegalovirus (CMV) infection and disease in adult Japanese kidney transplant recipients.","primaryOutcome":{"measure":"Percentage of Participants With Adverse Events (AEs)","timeFrame":"Up to week 52 post-transplant","effectByArm":[{"arm":"Letermovir","deltaMin":90.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":23},"locations":{"siteCount":4,"countries":["Japan"]},"refs":{"pmids":["38615067"],"seeAlso":["http://www.merckclinicaltrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":22},"commonTop":["Stomatitis","Diarrhoea","Neutrophil count decreased","Hyperlipidaemia","Anaemia"]}}